Clinical outcomes of renal and liver transplant patients undergoing transcatheter aortic valve replacement: analysis of national inpatient sample database. (3rd April 2021)

• Record Type: Journal Article
• Authors: Ullah, Waqas; Sattar, Yasar; Al-Khadra, Yasser; Mukhtar, Maryam; Darmoch, Fahed; Rajput, Nida; Hakim, Zaher; Zahid, Salman; Khan, Muhammad Zia; Fischman, David; Alraies, M. Chadi
• Is Part Of: Expert review of cardiovascular therapy. Volume 19:Number 4(2021)
• Page Start: 363
• Page End: 368
• Publication Date: 2021-04-03
• Subjects: Severe aortic valve stenosis -- aortic valve replacement -- transcatheter aortic valve replacement -- transcatheter aortic valve implantation -- renal transplant -- liver transplant; Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1080/14779072.2021.1892489
• Languages: English
• ISSNs: 1477-9072

Abstract

ABSTRACT: Background: The transcatheter aortic valve replacement (TAVR) has recently gained traction as a viable alternative to surgical aortic valve replacement (SAVR), but data on its safety and clinical outcomes in transplant patients are limited. Methods: We retrieved relevant demographic and clinical outcome data from the U.S. National Inpatient Sample (NIS) for the year 2012–2015. The clinical outcomes of TAVR in renal transplant (RT) and liver transplant (LT) were ascertained using an adjusted odds ratio (aOR) with a 95% confidence interval (CI) on Mantzel–Hensel test. Results: A total of 62, 399 TAVR patients were identified; 62, 180 (99.6%) with no history of transplant, 219 (0.4%) with RT and 85 (0.1%) with LT. There was no significant difference in odds of in-hospital mortality (OR 0.61, 95% CI 0.25–1.5, p = 0.37), major cardiovascular, respiratory or neurological complications in patients with and without RT. Similarly, the odds of cardiac complications, renal and neurological complications between patients with and without LT were identical. Conclusion: Compared to non-transplant patients, TAVR appears to be associated with similar odds of major systemic complications or mortality in patients with a history of kidney or liver transplant.